Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc - Preliminary results

Nephrology Dialysis Transplantation

Volumn 23, Issue 4, 2008, Pages 1241-1245

  Kimmel, Martin ^a   Butscheid, Moritz ^b   Brenner, Stefanie ^b   Kuhlmann, Ulrich ^a   Klotz, Ulrich ^b   Alscher, Dominik Mark ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Contrast induced nephropathy; Cystatin C; NAC; Volume expansion; Zinc

Indexed keywords

ACETYLCYSTEINE; CREATININE; CYSTATIN C; PLACEBO; ZINC; CONTRAST MEDIUM; CYSTATIN; DRUG DERIVATIVE; IOMEPROL; IOPAMIDOL; PROTEINASE INHIBITOR; SCAVENGER; ZINC DERIVATIVE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; ANGIOCARDIOGRAPHY; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; FEMALE; FOLLOW UP; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATININE; CYSTATINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FREE RADICAL SCAVENGERS; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, INTRAVENOUS; IOPAMIDOL; MALE; PROTEASE INHIBITORS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ZINC COMPOUNDS;

EID: 42949106192     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm785     Document Type: Article

References (35)

1. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Supp 2006; 69: S3-S7
2. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 69: S11-S15
3. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936
4. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494
5. Lassnigg A, Schmidlin D, Mouhieddine M et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004; 15: 1597-1605
6. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370
7. Weisbord SD, Chen H, Stone RA et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006; 17: 2871-2877
8. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-1953
9. Stevens LA, Coresh J, Greene T et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483
10. Hoffmann U, Fischereder M, Kruger B et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15: 407-410
11. Filler G, Bokenkamp A, Hofmann W et al. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005; 38: 1-8
12. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83
13. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226
14. Ognibene A, Mannucci E, Caldini A et al. Cystatin C reference values and aging. Clin Biochem 2006; 39: 658-661
15. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147
16. Durham JD, Caputo C, Dokko J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-2207
17. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS, New York: Springer, 2000, 1-96
18. Tepel M, Van Der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184
19. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113: 799-1806
20. Bagshaw SM, McAlister FA, Manns BJ, et al. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006; 166: 161-166
21. Lameire NH. Contrast-induced nephropathy-prevention and risk reduction. Nephrol Dial Transplant 2006; 21: i11-i23
22. Tepel M, Van Der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995
23. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379-386
24. Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-2782
25. Zagler A, Azadpour M, Mercado C et al. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 2006; 151: 140-145
26. Artunc FH, Fischer IU, Risler T et al. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102: 173-178
27. Herget-Rosenthal S, Pietruck F, Volbracht L, et al. Serum cystatin C - a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol 2005; 64: 41-46
28. Herget-Rosenthal S, Marggraf G, Husing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-1122
29. Rickli H, Benou K, Ammann P et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004; 61: 98-102
30. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 2006; 69: S8-S10
31. Alscher DM, Braun N, Biegger D et al. Induction of metallothionein in proximal tubular cells by zinc and its potential as an endogenous antioxidant. Kidney Blood Press Res 2005; 28: 127-133
32. Aspelin P, Aubry P, Fransson S et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499
33. Barrett B, Thomson H, Katzberg R. Nephrotoxicity of low-osmolar iopamidol vs iso-osmolar iodixanol in renally impaired patients: the IMPACT study. Invest Radiol 2006; 41: 815-821
34. Jo S, Youn TJ, Koo BW et al. Renal toxicity evaluation and comparison between visipaque (Iodixanol) and hexabrix (Ioxaglate) in atients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. JACC 2006; 48: 924-930
35. Solomon R, Natarajan MK, Doucet S et al. The CARE (Cardiac Angiography in REnally Impaired Patients) Study: a randomized, double blind trial of contrast-induced nephropathy in high risk patients. Circulation 2007; 115: 3189-3196